title: [Correction of adverse reactions in antimicrobial therapy of respiratory tract tuberculosis].
abstract: Hepatoprotective activity of succinate-containing solution (remaxol) in patients with respiratory tract tuberculosis subjected to specific antibacterial polychemotherapy was estimated by the clinical signs of the drug hepatotoxicity, the activity of cytolytic enzymes and the markers of the cholestatic syndrome in regard to the types of the adaptation reactions. The positive influence of remaxol on the signs of the drug hepatotoxicity and adaptation reactions was shown which was indicative of active use of the plastic substrates, increase of reparative processes in hepatocyte and decrease of the pathological types of reactivity in the patients with respiratory tract tuberculosis.
authors.forename: D S
authors.initials: DS
authors.lastname: Sukhanov
authors.forename: A L
authors.initials: AL
authors.lastname: Kovalenko
authors.forename: A Iu
authors.initials: AIu
authors.lastname: Petrov
authors.forename: M G
authors.initials: MG
authors.lastname: Romantsov
authors.forename: S B
authors.initials: SB
authors.lastname: Rybalkin
mesh_terms: D000293:Adolescent; D000328:Adult; D000995:Antitubercular Agents / Q000009:adverse effects* / Q000627:therapeutic use; D056486:Chemical and Drug Induced Liver Injury; D005260:Female; D006801:Humans; D008107:Liver Diseases / Q000517:prevention & control*; D008297:Male; D008875:Middle Aged; D019999:Pharmaceutical Solutions; D013386:Succinates / Q000627:therapeutic use*; D014397:Tuberculosis, Pulmonary / Q000188:drug therapy*; D055815:Young Adult
chemical_list: D000995:Antitubercular Agents; D019999:Pharmaceutical Solutions; C555877:Remaxol; D013386:Succinates